title: Pharmacokinetic models for the saturable absorption of cefuroxime axetil and saturable elimination of cefuroxime.
abstract: Since oligopeptidic drugs such as beta-lactam antibiotics share the same carriers in humans and animals, the absorption and elimination kinetics of cefuroxime (C) were investigated in rats. Plasma C concentrations were measured by liquid chromatography. Pharmacokinetics and bioavailability of C in the rat were examined after intravenous (i.v.) administration at three doses (1.78, 8.9 and 17.8mg) of cefuroxime sodium and oral administration at two doses (2.02 and 8.9mg) of cefuroxime axetil (CA). Preliminary fits using data from intravenous administration of C showed that the drug disposition kinetics were clearly nonlinear, with an increase in plasma clearance as the intravenous dose increased. After oral administration of CA, normalized C(max) was higher for smaller dose than for the largest dose. The population pharmacokinetic parameters were obtained by means of nonlinear mixed effect modelling approach according to a nonlinear elimination and nonlinear absorption two-compartment model. The nonlinear elimination could be attributed to a saturable renal tubular reabsorption of the antibiotic and nonlinear intestinal absorption of CA mediated by carrier system. The oral bioavailability of C, calculated by numeric integration of an amount of CA drug absorbed was 22 and 17% for 2.02 and 8.9mg of prodrug administered orally.
authors.affiliation: Departamento de Farmacia y Tecnologi;a Farmacéutica, Faculty of Pharmacy, University of Valencia, Avda, Vicente Andrés Estellés s/n, 46100 Burjassot, Valencia, Spain. matilde.merino@uv.es
authors.forename: P
authors.initials: P
authors.lastname: Ruiz-Carretero
authors.forename: M
authors.initials: M
authors.lastname: Merino-Sanjuán
authors.forename: A
authors.initials: A
authors.lastname: Nácher
authors.forename: V G
authors.initials: VG
authors.lastname: Casabó
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D001682:Biological Availability; D002444:Cefuroxime / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics*; D007275:Injections, Intravenous; D008297:Male; D008954:Models, Biological; D017711:Nonlinear Dynamics; D051381:Rats; D017208:Rats, Wistar; D013997:Time Factors
chemical_list: D000900:Anti-Bacterial Agents; D002444:Cefuroxime; C040738:cefuroxime axetil